Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk.

Journal of clinical lipidology - 1 Jan 2000

Saavedra Yascara G Luna, Dufour Robert, Baass Alexis

Abstract excerpt

BACKGROUND: Recent meta-analyses have shown a dose-dependent effect of statins therapy on the increased incidence of new-onset diabetes. Proprotein convertase subtilisin/kexin type (PCSK9) inhibitors are an important group of emerging lipid-lowering therapies. PCSK9 loss-of-function mutations have been associated with low-density lipoprotein cholesterol and cardiovascular risk, but their impact on glucose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cohort Studies
Share to Cross-Sectional Studies
Share to Hyperlipoproteinemia Type II

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polymorphism, Single Nucleotide

Share to Prediabetic State

Share to Proprotein Convertase 9

Share to Proprotein Convertases

Share to Serine Endopeptidases

Source

Identifiers

PMID: 26687699
DOI: 10.1016/j.jacl.2015.08.005

Genes

PCSK9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk.PMID 26687699Read ↗

PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes.Semantic proximity Read ↗

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.Semantic proximity Read ↗

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive SynopsisSemantic proximity Read ↗

LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy.Semantic proximity Read ↗

Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia.Semantic proximity Read ↗

Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype.Semantic proximity Read ↗

Clinical aspects of PCSK9.Semantic proximity Read ↗

PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.Semantic proximity Read ↗

The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis.Semantic proximity Read ↗

PCSK9 gene mutations and low-density lipoprotein cholesterol.Semantic proximity Read ↗

Loss-of-function mutation of PCSK9 as a protective factor in the clinical expression of familial hypercholesterolemiaSemantic proximity Read ↗

Protective lipid-lowering variants in healthy older individuals without coronary heart disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.